Ovoca Bio (OVB) Share Price, News & Analysis

Company Overview

Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia. Ovoca Bio is currently developing BP-101, a novel medicinal treatment for premenopausal women suffering from hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million women in the US with similar prevalence in other countries globally. The condition represents a significant area of high unmet medical need with few and challenging treatment options.

Key Stats

• Today's Range: N/A
• 50-Day Range: 1.05 to 1.28
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 128,595 shs
• Market Capitalization: £1.16 million
• P/E Ratio: N/A
• Dividend Yield: 0.83%
• Price Target: N/A
• Consensus Rating: N/A

OVB Stock Analysis - Frequently Asked Questions

How do I buy shares of Ovoca Bio?

Shares of OVB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Ovoca Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovoca Bio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and J D Wetherspoon (JDW).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OVB
• CIK: N/A
• Web: www.ovocabio.com
• Phone: 353 1 661 9819
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£1.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.49%
• Return on Assets: 3.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 1.00
• Book Value: GBX 2.41 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 100,664,663
• Free Float: N/A
• Market Cap: £1.16 million
• Optionable: Not Optionable
• Beta: 0.90